2 results
Approved WMOCompleted
Primary:Determine the MTD and/or RDE(s) of ABL001:* As a single agent for CML CP and AP patients* In combination with either nilotinib or imatinib or dasatinib in CML CP and AP patients* As a single agent for CML BP patients and Ph+ ALL…
Approved WMOPending
Phase I:Primary Objective:To determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK-positive solid tumors RP2D and, if applicable, the MTD as determined by incidence of DLTs during Cycle 1, overall safety profile, PK…